Avenue Therapeutics (NASDAQ:ATXI) Stock Jumps 6.7% – What’s Next?

Avenue Therapeutics, Inc. (NASDAQ:ATXI)’s share price rose 6.7% on Thursday. The company traded as high as $0.4289 and last traded at $0.4289. 117 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 6,508 shares. The stock had previously closed at $0.4019.

Avenue Therapeutics Price Performance

The firm has a market cap of $1.41 million, a P/E ratio of 0.02 and a beta of -0.32. The company has a fifty day moving average of $0.47 and a 200-day moving average of $0.36.

Avenue Therapeutics Company Profile

Avenue Therapeutics, Inc is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company has concentrated primarily on hospital-based treatments, with the goal of addressing pain management needs while offering alternatives to conventional opioid therapies.

Avenue’s lead product candidate is intravenous (IV) tramadol, an investigational formulation of tramadol hydrochloride intended for the management of acute postoperative pain in adults who require an intravenous analgesic.